Second generation integrase transcriptase inhibitors (INSTIs) currently represent the most highly recommended option for first-line ART • HIV-infected individuals with advanced disease (e.g. CD4 count <200 cells/mm3 or AIDS), are typically underrepresented or excluded from randomized controlled trials (RCTs) • As a consequence, superiority of INSTIs-based regimens to boosted-PI regimens in the specific target population of people with advanced HIV disease, has not been demonstrated • A single RCT is now ongoing comparing B/F/TAF to DRV/c/F/TAF in people with advanced HIV disease but first results are expected in late 2021 (the LAPTOP trial https://clinicaltrials.gov/ct2/show/NCT03696160) • Novel statistical methods exist that allow the use of observational data to emulate RCTs when randomized comparisons are missing

Emulation of an RCT of Dolutegravir vs boosted-darunavir in advanced art naïve

G. Nunnari;G. F. Pellicanò.
2020

Abstract

Second generation integrase transcriptase inhibitors (INSTIs) currently represent the most highly recommended option for first-line ART • HIV-infected individuals with advanced disease (e.g. CD4 count <200 cells/mm3 or AIDS), are typically underrepresented or excluded from randomized controlled trials (RCTs) • As a consequence, superiority of INSTIs-based regimens to boosted-PI regimens in the specific target population of people with advanced HIV disease, has not been demonstrated • A single RCT is now ongoing comparing B/F/TAF to DRV/c/F/TAF in people with advanced HIV disease but first results are expected in late 2021 (the LAPTOP trial https://clinicaltrials.gov/ct2/show/NCT03696160) • Novel statistical methods exist that allow the use of observational data to emulate RCTs when randomized comparisons are missing
978-1-7320053-3-4
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11570/3151811
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact